After treated with gemcitabine, only METTL14 was significantly increased in all six pancreatic cancer cell lines, but not METTL3, WTAP, VIRMA, FTO or ALKBH5 (Figures 1A–F). This evidence concerns the gene FTO and familial pancreatic carcinoma.